布地奈德与复方异丙托溴铵雾化吸入用于小儿哮喘治疗中的临床研究

Clinical Study of Budesonide and Compound Ipratropium Bromide Nebulized Inhalation in Pediatric Asthma Treatment

目的探讨对小儿哮喘采用布地奈德联合复方异丙托溴胺雾化吸入的临床效果。方法选择苏州市吴中人民医院2018年1月—2021年12月收治的小儿哮喘者80例,以随机数表法分为对照组(n=40,布地奈德联合沙丁胺醇治疗)与观察组(n=40,布地奈德联合复方异丙托溴铵治疗),比较两组临床疗效,典型症状改善时间与住院时间,并检测治疗前后第一秒用力呼气量(FEV1)、FEV1/用力肺活量(FVC)、呼气峰值流速(PEF)评估患儿肺功能,统计不良反应情况评估用药安全性。结果观察组总有效率较对照组高(97.50%vs80.00%),差异有统计学意义(χ^(2)=4.507,P<0.05)。治疗后,观察组咳痰咳嗽、肺哮鸣音、呼吸困难、肺啰音改善时间与住院时间分别为(4.51±1.74)、(3.59±1.36)、(2.75±1.27)、(2.65±1.15)、(4.60±1.52)d,均短于对照组,差异有统计学意义(t=3.789、5.404、6.664、7.356、4.623,P<0.05)。观察组FEV1、FEV1/FVC、PEF水平分别为(1.72±0.16)L、(82.12±7.80)%、(4.20±0.58)L/s,均高于对照组,差异有统计学意义(t=6.633、3.891、5.811,P<0.05)。两组不良反应发生率(5.00%vs 10.00%)差异无统计学意义(χ^(2)=0.180,P>0.05)。结论对小儿哮喘予以布地奈德联合复方异丙溴铵进行雾化吸入可提升治疗效果,能加快哮喘症状的缓解,且可提高肺功能。

Objective To investigate the clinical effect of using budesonide combined with compound ipratropium bromide by nebulized inhalation for pediatric asthma.Methods Eighty cases of pediatric asthma admitted to Wuzhong People’s Hospital in Suzhou from January 2018 to December 2021 were selected and divided into control group(n=40,budesonide combined with salbutamol treatment)and observation group(n=40,budesonide combined with compound ipratropium bromide treatment)by random number table method.Compare the clinical efficacy,improvement time of typical symptoms and hospitalization time of the two groups.The first second expiratory volume(FEV1),FEV1/exertional spirometry(FVC),and peak expiratory flow rate(PEF)were measured before and after treatment to assess the lung function of the children,and the adverse effects were counted to assess the safety of the medication.Results The total effective rate of the observation group was higher than that of the control group(97.50%vs 80.00%),and the difference was statistically significant(χ^(2)=4.507,P<0.05).After treatment,the improvement time of coughing and coughing,pulmonary croup,dyspnea,and pulmonary rales and hospitalization time in the observation group were(4.51±1.74),(3.59±1.36),(2.75±1.27),(2.65±1.15),and(4.60±1.52)d,respectively,which were shorter than those in the control group,and the differences were statistically significant(t=3.789,5.404,6.664,7.356,4.623,P<0.05).The FEV1,FEV1/FVC,and PEF levels in the observation group were(1.72±0.16)L,(82.12±7.80)%,and(4.20±0.58)L/s,respectively,which were higher than those in the control group,and the differences were statistically significant(t=6.633,3.891,5.811,P<0.05).The difference in the incidence of adverse reactions between the two groups(5.00%vs 10.00%)was not statistically significant(χ^(2)=0.180,P>0.05).Conclusion Nebulized inhalation of budesonide combined with compound ipratropium bromide in pediatric asthma can enhance the therapeutic effect,accelerate the relief of asthma symptoms,and improve lung function.